INCY · NASDAQ
Incyte Corporation
$113.31 -1.22 (-1.04%)
Company overview
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that acts as an oncogenic driver in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in a Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $23B
- Employees
- 2,617
- Headquarters
- Wilmington, DE
- Website
- incyte.com
- CEO
- William J. Meury
- Listed
- November 4, 1993
- P/E
- 15.52
- Dividend yield
- 0.00%
Company financials
- Revenue
- $5.4B
- Gross profit
- $5B
- Operating income
- $1.5B
- EBITDA
- $1.9B
- Net income
- $1.4B
- EPS
- $7.30
- Total assets
- $7.3B
- Total debt
- $33.8M
- Gross margin
- 92.48%
- Net margin
- 26.71%
- Earnings yield
- 6.44%
Showing FY 2025
INCY
1D
NASDAQ
O115.02H115.59L112.83C113.21-2.50 (-2.16%)Vol517.02K